News

Pharma spending on US doctors topped $1 billion last year as the industry braces for the arrival of the Sunshine Act.

Around 20% of clinical trials currently underway are using adaptive designs, while adoption of these techniques is likely to increase significantly over the next few years, particularly in the exploratory phase of drug development, a new report suggests.

Valeant Pharmaceuticals has acquired the eye health company Bausch & Lomb for $8.7 billion in cash.

Australian patients are missing out on some new medicines because the process of listing them on the Pharmaceutical Benefit Scheme (PBS) has become too difficult, say industry leaders.

Cenix BioScience, a preclinical contract research organisation specialising in drug discovery based on RNA interference (RNAi), micro-RNA (miRNA) and high-content screening, has signed a research agreement to support Switzerland’s Debiopharm Group in its efforts to develop personalised therapies for unmet medical needs.

The care of patients with dementia and complex health needs has been given priority in plans to improve the training, values and education of National Health Service staff.

UK-based stem-cell pioneer ReNeuron has reported further encouraging data from the Phase I PISCES (Pilot Investigation of Stem Cells in Stroke) study of its ReN001 therapy in ischaemic-stroke patients.

The amount of money allocated to GPs in England to care for their patients is set to fall by nearly £200 million over the next three years, equal to the current funding for 1.2 million patients, the Royal College of General Practitioners (RCGP) has warned.

Healthcare organisations expanding into emerging markets like Brazil, Russia, India and China (BRIC) are now realising that there are no shortcuts, and they need to be changing the dialogue around these nations, according to a new report.

GeneWatch UK says the UK Government’s is looking to build a DNA database by stealth in the NHS in England, according to a new report.

Johnson & Johnson says it is looking to have ten new pharma products on the market in the next four years as it looks to build on a strong 2012.

New survey of NHS professionals finds a vast majority do not believe that quality of care in the health service is given enough priority.

A panel of experts at the US Food and Drug Administration has recommended Merck & Co’s insomnia drug suvorexant when given in lower dosages but rejected the higher dose that the company was seeking.

As Ranbaxy Laboratories laid out some of the actions it has taken “to address certain conduct of the past” to ensure the safety of its products, reports are circulating that the Indian drugmaker could shed up to a third of its salesforce.

Companies and individuals have been recognised for their excellence in advancing the future skills required for the life sciences industry at the inaugural UK Life Sciences Skills Awards, organised by Cogent.